Achieve Life Sciences, Inc. (ACHV) Financial Statements
Free cash flow over the same period: -$49.5M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ACHVAchieve Life Sciences, Inc.Follow ACHV — free
—
Price chart with a free account
- Market cap
- 667.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research & development | 21.6 | 39.9 | 55.3 | 46.2 | 25.1 | 0.3 | 3.1 | 5.9 | 9.7 | 6.9 | 24.0 | 30.1 | 15.8 | 22.8 | — | — | |
| Pre-tax income | -14.7 | -21.1 | -31.8 | -26.2 | -0.8 | -1.7 | -13.6 | -12.7 | -16.4 | -14.7 | -33.2 | -42.4 | -29.8 | -39.8 | -54.6 | -114.0 | |
| Income tax | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — | — | — | — | — | — | — | — | |
| Net income | -14.7 | -21.1 | -31.8 | -26.2 | -0.8 | -1.2 | -10.6 | -12.7 | -16.4 | -14.7 | -33.2 | -42.4 | -29.8 | -39.8 | -54.6 | -114.0 | |
| Diluted EPS ($) | -1.51 | -1.56 | -2.17 | -1.45 | -39.00 | -581.25 | -22.07 | -72.29 | -39.76 | -5.42 | -4.08 | -4.00 | -1.50 | -1.24 | -1.25 | -1.22 | |
| Diluted shares (mn) | — | — | — | — | — | — | — | — | — | — | — | 10.6 | 19.8 | 32.1 | 43.6 | — |
USD millions · SEC XBRL
Achieve Life Sciences, Inc. — questions
- What is Achieve Life Sciences, Inc.'s net income?
- -$114.0M over the twelve months to 2026-06-30.
- What is Achieve Life Sciences, Inc.'s free cash flow?
- -$49.5M over the twelve months to 2026-06-30.
- What are Achieve Life Sciences, Inc.'s diluted earnings per share?
- $-1.22 over the twelve months to 2026-06-30.
Every figure on this page comes from Achieve Life Sciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.